Phase III KEYNOTE-240: Second-line Treatment With Pembrolizumab + BSC vs Placebo + BSC in Advanced Hepatocellular Carcinoma

May 31 - June 4, 2019; Chicago, Illinois
In KEYNOTE-240, pembrolizumab showed nonsignificant improvement in PFS and OS compared with placebo as second-line therapy in advanced HCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 216 KB
Released: June 4, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Blueprint Medicines
Celgene Corporation
Taiho Oncology Inc.

Related Content

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Slides from Clinical Care Options (CCO) on histology-agnostic biomarker testing to guide therapy for gastrointestinal cancer

John L. Marshall, MD Released: July 15, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to HCP questions on immunotherapy for patients with advanced HCC

Released: June 29, 2021

Video from Clinical Care Options (CCO) featuring expert insights into current and upcoming immunotherapy approaches for HCC

David Kaplan, MD, MSc person default Thomas Karasic, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 21, 2021 Expired: June 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue